TM
WST icon

Taproot Management’s West Pharmaceutical WST Stock Holding History

Taproot Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,673
Closed -$10.9M – 170
2026
Q1 		$10.9M Sell
43,673
-1,085
-2% -$270K 2.07% 2
2025
Q4 		$12.3M Buy
+44,758
New +$12.2M 2% 5

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Taproot Management's WST Position: Q2 2026 in Review

Taproot Management sold out of West Pharmaceutical (WST) in Q2 2026, closing a stake of 43,673 shares — an estimated $10.9M sold.

Taproot Management first reported a position in WST in Q4 2025 and held it in 2 quarters. The position peaked at $12.3M in Q4 2025. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Taproot Management reported no remaining West Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Taproot Management sold 43,673 West Pharmaceutical shares in Q2 2026, an estimated $10.9M.
  • Taproot Management first reported a position in West Pharmaceutical in Q4 2025 and held it in 2 quarters.
  • Taproot Management's West Pharmaceutical position peaked at $12.3M in Q4 2025.
  • 834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Taproot Management's 13F filing for Q2 2026.